Miranker awarded two grants to support research and new biotech company

April 16, 2018

Andrew Miranker has been awarded $600,000 for continuing his research on diabetes from the Connecticut Bioscience Innovation Fund and the Blavatnik Fund for Innovation at Yale. These funds were awarded in part as a result of an article published in Nature Communications and will be used for further research on type 2 diabetes, specifically on a protein known as islet amyloid polypeptide. Drug therapies will be researched at ADM Therapeutics in Connecticut, a new biotechnology company being formed. See details in the Yale News article.